Full history for every metric is available with a Kvantra account
Verve Therapeutics, Inc. (VERV)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 2 | 12 | 32 | 60 |
| Operating profit | $m | -229 | -208 | |||||
| Net profit | $m | -19 | -46 | -119 | -157 | -200 | -199 | -181 |
| EPS reported | $ | -2.35 | -2.11 | |||||
| Operating cashflow per share | $ | -1.86 | -1.86 | |||||
| Capex per share | $ | 0.04 | 0.04 | |||||
| FCF per share | $ | -1.91 | -1.91 | |||||
| Free cash flow | $m | -161 | -147 | |||||
| Net debt | $m | -524 | -497 | |||||
| Book value equity | $m | 493 | 474 | |||||
| Book value per share | $ | 5.82 | 5.33 | |||||
| Number of shares | m | 84.72 | 88.8 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.97 | 2.10 | |||||
| P/S LTM | x | 14.78 | 16.67 | |||||
| P/FCF LTM | x | -2.96 | -6.76 | |||||
| EV/EBITDA LTM | x | -1.69 | -2.46 | |||||
| EV/Sales LTM | x | 11.61 | 8.34 | |||||
| Earnings Yield LTM | % | -41.59% | -21.07% | |||||
| FCF Yield | % | -33.78% | -14.79% | |||||
| Quality | ||||||||
| ROE | % | -40.27% | -36.36% | |||||
| ROIC | % | -37.19% | -37.19% | |||||
| Operating margin | % | -707.23% | -707.23% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -499.28% | -499.28% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +174.98% | +271.44% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.31 | -2.14 | |||||
| Net Debt/EBITDA | x | 0.46 | 0.46 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -109.72% | -50.01% | |||||
| Net debt/Equity | x | -1.06 | -1.05 | |||||
| Gross debt/equity | x | 0.14 | 0.14 | |||||
Company overview
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Verve Therapeutics, Inc. (VERV)
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free